Phendimetrazine Tartrate Capsule, Extended Release
NDC Package 72989-409-11
Package Information
Phendimetrazine Tartrate capsules is phendimetrazine tartrate extended-release capsules are indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of greater than or equal to 30 kg/m2 or greater than or equal to 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia) who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone.Below is a chart of Body Mass Index (BMI) based on various heights and weights. This formulation utilizes a capsule, extended release delivery system. Marketed by Acertis Pharmaceuticals, Llc, this product is identified by NDC 72989-409 and is authorized under FDA application NDA018074.
Identification & Billing
- RxCUI: 979543 - phendimetrazine tartrate 105 MG 24HR Extended Release Oral Capsule
- RxCUI: 979543 - 24 HR phendimetrazine tartrate 105 MG Extended Release Oral Capsule
- RxCUI: 979543 - phendimetrazine 105 MG 24 HR Extended Release Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72989 - Acertis Pharmaceuticals, Llc
- 72989-409 - Phendimetrazine Tartrate
- 72989-409-11 - 1000 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
- 72989-409 - Phendimetrazine Tartrate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (72989-409). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72989-409-11 identifies a specific commercial package of 1000 capsule, extended release in 1 bottle of Phendimetrazine Tartrate, a human prescription drug labeled by Acertis Pharmaceuticals, Llc. This capsule, extended release is formulated for oral use and contains phendimetrazine tartrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Acertis Pharmaceuticals, Llc on November 01, 2022. The current certification is valid through December 31, 2027.
How is this Acertis Pharmaceuticals, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72989040911. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.